A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 mg Daily Of Imatinib.

Trial Profile

A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 mg Daily Of Imatinib.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Imatinib; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Jul 2017 This trial has been completed in UK (on-2009-11-23), according to European Clinical Trials Database.
    • 19 Jan 2010 Actual patient number (60) added as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Actual patient number (60) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top